marked.bio

Company

Teligene

4 active trials that select patients by a biomarker on marked.bio, across 2 biomarkers.

Counts only trials this company leads as sponsor, not partnered or academic trials of its drugs.

Biomarkers

Drugs in these trials

Targeted, immune and antibody-drug-conjugate therapies named in the company's active biomarker-selected trials (including other companies' drugs used in combination).

trastuzumab 1

Upcoming readouts

Active phase 2 and 3 trials whose primary completion date falls in the next 12 months, according to the sponsor.

Trials

4 of 4 trials shown

  1. TL938 and Trastuzumab for Patients With HER2-positive Metastatic Colorectal Cancer

    Recruiting Phase 2 Teligene Started 2025Primary completion 2026-10 NCT06589830

    TL938 Capsulestrastuzumab

    …ere deficient in mismatch repair (dMMR) proteins or were microsatellite instability-high (MSI-H) must also have received an ant-programmed cell death protain-1 mAb;

    MSI-H / dMMRColorectal Cancer Metastatic, Advanced Colorectal Cancer

  2. A Study to Evaluate the Efficacy and Safety of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC

    Recruiting Phase 2 Teligene Started 2023Primary completion 2027-12 NCT06010329

    Sutetinib Maleate Capsule

    …ficacy and Safety of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC (Uncommon EGFR Mutations Only)

    EGFR exon 19 deletion / L858RNon-small Cell Lung Cancer

  3. A Study to Evaluate the Efficacy and Safety of TL118 in Solid Tumors Patients

    Recruiting Phase 2 Teligene Started 2023Primary completion 2027-12 NCT06010342

    TL118 Capsule

    …gically confirmed diagnosis of locally advanced or metastatic solid tumor that harbors an NTRK1/2/3 gene fusion that is predicted to translate into a fusion protein with a functional tropomyosin recept…

    NTRK1/2/3 fusionSolid Tumor

  4. Study to Evaluate Sutetinib Maleate Capsule in Locally Advanced or Metastatic Non-small Cell Lung Cancer

    Recruiting Phase 2 Teligene Started 2022Primary completion 2027-12 NCT05168566

    Sutetinib Maleate Capsule

    Confirmation that the tumor harbors a non-resistant uncommon EGFR mutation (tumor tissue biopsy), including one or more of L861Q, G719X and S768I mutations, excludi…

    EGFR exon 19 deletion / L858RNon-small Cell Lung Cancer